Abciximab (Reopro, Abcixifiban): Difference between revisions

Abciximab (Reopro, Abcixifiban) (view source)

Revision as of 17:32, 9 May 2023

1,029 bytes added , 9 May 2023

no edit summary

Danesthesia

Bureaucrats, Interface administrators, Administrators

1,522

edits

@@ Line 8: / Line 8: @@
 Abciximab, sold under the brand names Reopro and Abcixifiban, is a medication used to prevent blood clots in people undergoing coronary angioplasty. It is a glycoprotein IIb/IIIa inhibitor, which means that it blocks the platelets in the blood from aggregating and forming clots. This medication is administered intravenously during the procedure, usually in combination with heparin and aspirin.
-Abciximab was first approved by the United States Food and Drug Administration (FDA) in 1994 for use during coronary angioplasty. Since then, it has also been approved for use in preventing blood clots during other cardiovascular procedures, such as coronary artery bypass surgery and stent placement.
+==Mechanism of action==
+Abciximab blocks the glycoprotein IIb/IIIa receptor on the surface of platelets, preventing the binding of fibrinogen and other ligands that are necessary for platelet aggregation and clot formation.
-Some common side effects of abciximab include bleeding, bruising, and low blood pressure. In rare cases, it can cause severe allergic reactions or blood clotting disorders.
+==Indications==
+Abciximab is primarily used to prevent blood clots during cardiovascular procedures, such as:
-Overall, Abciximab has been found to be an effective medication in preventing blood clots during cardiovascular procedures. However, it should only be used under the guidance of a healthcare provider and with careful monitoring due to its potential side effects.
+    Coronary angioplasty
+    Coronary artery bypass surgery
+    Stent placement
+It may also be used in other situations where the risk of blood clots is high.
+==Required laboratory tests==
+Before administering abciximab, healthcare providers may order laboratory tests to assess the patient's blood clotting function, including:
+    Platelet count
+    Prothrombin time (PT)
+    Activated partial thromboplastin time (aPTT)
+    International normalized ratio (INR)
+==Dosing for every route of administration==
+The dosing of abciximab varies depending on the indication and the patient's weight. It is administered intravenously during the procedure.
+For coronary angioplasty, the typical dosing regimen is:
+    A bolus of 0.25 mg/kg over 1-2 minutes
+    A maintenance infusion of 0.125 μg/kg/min for 12 hours
+For coronary artery bypass surgery, the typical dosing regimen is:
+    A bolus of 0.25 mg/kg over 1-2 minutes
+    A maintenance infusion of 0.125 μg/kg/min for up to 24 hours
+For stent placement, the typical dosing regimen is:
+    A bolus of 0.25 mg/kg over 1-2 minutes
+    A maintenance infusion of 10 μg/min for up to 12 hours
+==Adverse reactions==
+Some common adverse reactions associated with abciximab include:
+    Bleeding
+    Bruising
+    Low blood pressure
+In rare cases, it can cause severe allergic reactions or blood clotting disorders, such as:
+    Thrombocytopenia
+    Thrombosis
+    Hemorrhage
 ==References==